Eisai started 'EWAY 2025', the medium-term business plan up to fiscal year 2025, in April 2016. For a pharmaceutical company which has conducted development of medicines over the course of many years, a decade is certainly not a long period of time. Eisai will endeavor to make steady contributions to patients with looking ahead the goal which must be reached 10 years later.
'EWAY 2025' aims to achieve the following three strategic intents:
- 1.Aim to support patients' thought: "I do not want to get sick. I want to know if I get sick, and I want to be cured."
- 2.Aim to support patients' thought: "I want to control my disease in my neighborhood and safely spend the rest of my life with peace of mind."
- 3.Focus on a business domain where Eisai can find out "Ricchi" based on hhc needs and fulfill them with Eisai innovation
What is "Ricchi"
Areas where real patient needs are still unmet, and where Eisai can become a frontrunner
"Ricchi" in Neurology area
- 1.Early and minimally-invasive diagnostics
- 2.Novel neuro-transmission pathways
- 4.Neuro-inflammation and immuno-genetics
- 5.Synapse micro-environment
- 6.Neuronal regeneration
Accelerate Development of Flagship Pipeline in Neurology Areas under Business Group Structure
Eisai has established business groups, end-to-end organizations that integrate functions from research and development to commercial, in the two major areas of neurology and oncology, upon the initiation of 'EWAY 2025'. One of the objectives of the establishment of business groups is to enhance productivity in business through Early Decision Making. Another is to develop Scientific Acumen, an important organizational culture, through integrated business structure which includes discovery research. Development of flagship drugs based on "Ricchi" in neurology areas is accelerating since the organizational shift to business group structure has been made.
The Neurology Business Group (NBG) aims to realize prevention and cure in the field of dementia by leveraging the experience, knowledge and know-how accumulated over 30 years of developing new dementia drugs and conducting information provision activities relating to Aricept.